Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
5.78
+0.04 (0.70%)
Nov 7, 2025, 4:00 PM EST - Market closed
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $2.17M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $6.87M, up 84.67% year-over-year. In the year 2024, Armata Pharmaceuticals had annual revenue of $5.17M with 14.24% growth.
Revenue (ttm)
$6.87M
Revenue Growth
+84.67%
P/S Ratio
30.45
Revenue / Employee
$114,467
Employees
60
Market Cap
209.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARMP News
- 16 days ago - Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ - PRNewsWire
- 24 days ago - Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology - PRNewsWire
- 2 months ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PRNewsWire